David Erritzoe is the Deputy Head and Clinical Director of the Centre for Psychedelic Research at Imperial College London and Director of the CNWL-Imperial Psychopharmacology & Psychedelic Research (CIPPRes) Clinic at St. Charles Hospital. With more than 70 research publications and deep expertise in psychopharmacological research using brain imaging techniques, he is currently heading investigations on several psychedelic compounds including investigations on the mechanisms of ketamine's therapeutic effects, the role of 5HT2A receptors and 5HT release capacity in depression, and Phase I & II clinical trials on DMT in major depression.
